P Michael Grossman
Overview
Explore the profile of P Michael Grossman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
778
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gondi K, Tam M, Chetcuti S, Pagani F, Grossman P, Deeb G, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
2(1):100530.
PMID: 39132542
Background: Aortic regurgitation (AR) is common and detrimental in patients with left ventricular assist devices (LVADs). Off-label use of transcatheter aortic valve replacement (TAVR) has emerged as a potential treatment...
2.
Gualano S, Seth M, Gurm H, Sukul D, Chetcuti S, Patel H, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
1(3):100038.
PMID: 39131953
Background: Acute kidney injury (AKI) after contrast-guided interventions is associated with adverse outcomes, but the role of contrast in the context of renal function is less well described for patients...
3.
Khaleel I, Harris A, Seth M, Sukul D, Deeb G, Joseph M, et al.
JACC Adv
. 2024 Jun;
2(9):100641.
PMID: 38938726
Background: Prior studies of aortic valve replacement (AVR) in patients with normal-flow, low-gradient aortic stenosis (NF-LG AS) have demonstrated conflicting results regarding the survival benefit of AVR. Changes in quality...
4.
Sukul D, Albright J, Thompson M, Villablanca P, Keteyian S, Yaser J, et al.
JACC Adv
. 2024 Jun;
2(8):100581.
PMID: 38938330
Background: Cardiac rehabilitation (CR) is strongly recommended for a spectrum of cardiovascular conditions and procedures including aortic valve replacement. Objectives: The purpose of this study was to characterize patient and...
5.
Zaid S, Attizzani G, Krishnamoorthy P, Yoon S, Palma Dallan L, Chetcuti S, et al.
JACC Cardiovasc Interv
. 2023 Jul;
16(13):1626-1635.
PMID: 37438029
Background: The latest-generation Evolut FX TAVR system (Medtronic) offers several potential design improvements over its predecessors, but early reported experience has been limited. Objectives: This study sought to report our...
6.
Hawkins R, Deeb G, Sukul D, Patel H, Gualano S, Chetcuti S, et al.
JACC Cardiovasc Interv
. 2023 Apr;
16(8):942-953.
PMID: 37100557
Background: Aortic stenosis treatment should consider risks and benefits for lifetime management. Although the feasibility of redo transcatheter aortic valve replacement (TAVR) remains unclear, concerns are emerging regarding reoperation after...
7.
Grossman P, Sukul D, Lall S, Villablanca P, Shannon F, Seth M, et al.
JACC Cardiovasc Interv
. 2023 Jan;
16(2):168-176.
PMID: 36697152
Background: The 30-day rate of stroke after transcatheter aortic valve replacement (TAVR) has been suggested as a hospital quality metric. Thirty-day stroke rates for nonsurgical, high, and moderate-risk TAVR trials...
8.
Ho P, ODonnell C, McCreight M, Bavry A, Bosworth H, Girotra S, et al.
J Am Heart Assoc
. 2022 Jun;
11(13):e024342.
PMID: 35766258
Background P2Y12 inhibitor medications are critical following percutaneous coronary intervention (PCI); however, adherence remains suboptimal. Our objective was to assess the effectiveness of a multifaceted intervention to improve P2Y12 inhibitor...
9.
Fukuhara S, Tanaka D, Brescia A, Wai Sang S, Grossman P, Sukul D, et al.
J Thorac Cardiovasc Surg
. 2021 Sep;
165(6):2011-2020.e5.
PMID: 34538638
Background: Despite the rapid adoption of transcatheter aortic valve replacement since its approval, the frequency and outcomes of aortic valve reintervention after transcatheter aortic valve replacement are poorly understood. Methods:...
10.
Brescia A, Deeb G, Wai Sang S, Tanaka D, Grossman P, Sukul D, et al.
Circ Cardiovasc Interv
. 2021 Mar;
14(4):e009927.
PMID: 33719506
Background: Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) since its initial approval in 2011, the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly...